Most Recent
AstraZeneca has denied claims by Pharmacor that a patent for its diabetes drug Forxiga is invalid and that an extension of the patent's term was wrongly granted.
China-based Hytera Communications wants the High Court to overturn a finding that it stole Motorola's source code for its digital mobile radios, arguing the appeal raises important issues about how "substantial part" should be assessed under the Copyright Act.
Industry standards group Meat & Livestock Australia can bring a cross-claim for indemnity against the Agricultural Business Research Institute while defending a case alleging it infringed a patent for inferring bovine gene traits.
AstraZeneca has slammed Pharmacor's defence to claims it infringed a patent for blockbuster diabetes drug Forxiga as a "complete shot in the dark", as the drug maker unsuccessfully fought orders to produce documents from a UK case.
An employee of e-commerce merchandise importer New Aim wants the High Court to overturn a ruling that found he breached his duty of confidence by providing competitors with contact details of the company's suppliers, stored on WeChat on his personal phone.
Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.
Pharmacor, which is facing infringement claims by AstraZeneca over its plans to launch a generic version of diabetes drug Forxiga, can tweak its cross-claim to challenge a patent term extension.
Pharmacor has accused AstraZeneca of launching a royal commission into emails with its lawyers as AstraZeneca opposes the generic drug maker's bid to amend its pleading in a patent case over diabetes drug Forxiga.
The Full Court has found an employee of e-commerce merchandise importer New Aim breached his duty of confidence by providing contact details of the company's suppliers, stored on WeChat on his personal phone, to a competitor.
Melbourne-based biopharma Telix has filed a lawsuit against Purdue Research Foundation seeking to invalidate its patent for blockbuster prostate cancer treatment Pluvicto.